Issued 2026-09-16 at $17.53 · now $17.54 (2026-09-17, +0.1% since)
Based on its own history, a month from the 2026-09-16 close, TIPT has typically landed between $15.25 and $19.95 — a range of −13.0% to +13.8% from the issuance price $17.53.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
4,813 overlapping 1 month windows · 2007-06-22 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).
The cone is anchored at the 2026-09-16 issuance close ($17.53) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where TIPT has typically landed a month from the 2026-09-16 close of $17.53 — the range is history, not a prediction.
- now $17.54 (+0.1%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $17.77 (+1.4%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $16.83–$18.72
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $15.25–$19.95
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2009-02-02 | −50.9% | −50.9% | +1.8% |
| 2009-02-03 | −49.0% | −51.7% | +0.0% |
| 2009-02-05 | −45.3% | −50.4% | +2.9% |
| 3 best | |||
| 2021-03-24 | +96.1% | +0.0% | +96.1% |
| 2021-03-04 | +88.5% | +0.0% | +88.5% |
| 2021-03-08 | +86.6% | +0.0% | +86.6% |
4,814 overlapping windows · 2007-06-22 – 2026-09-17 · not cherry-picked
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Reported insider & political trades
Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.
| Date | Person | Role | Action | Shares @ price | Value | Ownership Δ | vs S&P 1m | vs S&P 6m | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | Ilany Jonathan | director | Purchase | 990 @ $17.45 | $17K | +0.5% of holding | +5.0% | not yet — horizon still open | 193,011 | Form 4 · filed 1 day after the trade |
| 2026-03-12 | McKinney Scott T. | officer | Purchase | 1,232 @ $15.98 | $20K | +44.5% of holding | +4.0% | −3.7% | 4,000 | Form 4 · filed 1 day after the trade |
| 2026-03-11 | McKinney Scott T. | officer | Purchase | 2,600 @ $16.15 | $42K | +1547.6% of holding | +3.9% | −1.2% | 2,768 | Form 4 · filed 2 days after the trade |
| 2025-11-07 | Mielle Dominique | director | Purchase | 5,500 @ $18.29 | $101K | +8.4% of holding | −5.2% | −17.8% | 70,712 | Form 4 · filed 3 days after the trade |
| 2025-03-25 | Rifkind Neil Charles | officer | Sale | 16,641 @ $25.00 | $416K | −51.5% of holding | −3.9% | −19.2% | 15,660 | Form 4 · filed 1 day after the trade |
The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.
57 award / exercise / gift records — not counted as purchases
Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.
| Date | Person | Role | Action | Shares | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-07-02 | Smith Bradley E. | director | Award / grant | 1,768 | 107,263 | Form 4 |
| 2026-07-02 | Goldwasser Lesley | director | Award / grant | 1,061 | 116,615 | Form 4 |
| 2026-04-02 | Smith Bradley E. | director | Award / grant | 1,907 | 105,495 | Form 4 |
| 2026-04-02 | Goldwasser Lesley | director | Award / grant | 1,144 | 115,554 | Form 4 |
| 2026-02-20 | McKinney Scott T. | officer | Withheld for tax | 5,143 | 99,939 | Form 4 |
| 2026-02-20 | McKinney Scott T. | officer | Option exercise | 15,110 | 105,082 | Form 4 |
| 2026-02-20 | McKinney Scott T. | officer | Option exercise | 15,110 | 0 | Form 4 |
| 2026-02-20 | McKinney Scott T. | officer | Option exercise | 15,110 | 105,082 | Form 4 |
| 2026-02-20 | McKinney Scott T. | officer | Option exercise | 15,110 | 0 | Form 4 |
| 2026-01-08 | Goldwasser Lesley | director | Award / grant | 2,048 | 114,410 | Form 4 |
| 2026-01-08 | Friedman Paul M | director | Award / grant | 2,048 | 122,398 | Form 4 |
| 2025-10-03 | Friedman Paul M | director | Award / grant | 1,807 | 120,350 | Form 4 |
| 2025-10-03 | Goldwasser Lesley | director | Award / grant | 1,807 | 112,362 | Form 4 |
| 2025-09-15 | Ilany Jonathan | director | Withheld for tax | 124,787 | 274,742 | Form 4 |
| 2025-09-15 | Ilany Jonathan | director | Withheld for tax | 98,531 | 399,529 | Form 4 |
| 2025-09-15 | Ilany Jonathan | director | Option exercise | 351,155 | 498,060 | Form 4 |
| 2025-09-15 | Ilany Jonathan | director | Option exercise | 351,155 | 0 | Form 4 |
| 2025-09-12 | Barnes Michael Gene | director | Withheld for tax | 29,224 | 10,085,428 | Form 4 |
| 2025-09-12 | Barnes Michael Gene | director | Option exercise | 112,015 | 10,114,652 | Form 4 |
| 2025-09-12 | Barnes Michael Gene | director | Option exercise | 112,015 | 0 | Form 4 |
| 2025-09-12 | Barnes Michael Gene | director | Withheld for tax | 10,343 | 9,999,059 | Form 4 |
| 2025-09-12 | Barnes Michael Gene | director | Option exercise | 46,494 | 0 | Form 4 |
| 2025-09-12 | Barnes Michael Gene | director | Option exercise | 46,494 | 10,009,402 | Form 4 |
| 2025-09-12 | Barnes Michael Gene | director | Withheld for tax | 1,071 | 10,002,637 | Form 4 |
| 2025-09-12 | Barnes Michael Gene | director | Option exercise | 4,649 | 10,003,708 | Form 4 |
| 2025-09-12 | Barnes Michael Gene | director | Option exercise | 4,649 | 0 | Form 4 |
| 2025-09-02 | Ilany Jonathan | director | Withheld for tax | 53,128 | 146,905 | Form 4 |
| 2025-09-02 | Ilany Jonathan | director | Option exercise | 137,038 | 223,035 | Form 4 |
| 2025-09-02 | Ilany Jonathan | director | Option exercise | 137,038 | 0 | Form 4 |
| 2025-09-02 | Ilany Jonathan | director | Withheld for tax | 33,262 | 189,773 | Form 4 |
| 2025-09-02 | Ilany Jonathan | director | Withheld for tax | 3,444 | 200,033 | Form 4 |
| 2025-09-02 | Ilany Jonathan | director | Option exercise | 13,704 | 0 | Form 4 |
| 2025-09-02 | Ilany Jonathan | director | Option exercise | 13,704 | 203,477 | Form 4 |
| 2025-07-03 | Goldwasser Lesley | director | Award / grant | 1,595 | 110,555 | Form 4 |
| 2025-07-03 | Friedman Paul M | director | Award / grant | 1,595 | 118,543 | Form 4 |
| 2025-04-03 | Friedman Paul M | director | Award / grant | 1,547 | 116,948 | Form 4 |
| 2025-04-03 | Goldwasser Lesley | director | Award / grant | 1,547 | 108,960 | Form 4 |
| 2025-02-25 | Ilany Jonathan | director | Withheld for tax | 65,781 | 85,997 | Form 4 |
| 2025-02-25 | Barnes Michael Gene | director | Award / grant | 60,813 | 9,962,908 | Form 4 |
| 2025-02-25 | Ilany Jonathan | director | Award / grant | 151,778 | 151,778 | Form 4 |
Source: SEC Form 4 filings. Each row links to its original filing.
Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.